Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.
General Instructions provides useful general background information for successfully completing forms.
2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.
Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.
Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.
Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.
Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms
Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.
Appendices provide additional information beyond the scope of the other manuals.
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.
|4/19/19||Multiple Myeloma Response Criteria||Modify|| Modified (struck out text has been deleted and red text has been added) the response criteria for Relapse from CR:
Relapse from CR
Requires one or more of the following:
|4/19/19||Waldenstrom’s Macroglobulinemia Response Criteria||Add|| Added (in red below) the following text for the Progressive Disease response criteria:
Progressive disease (PD)
|4/19/19||2131: ID Post-HCT||Modify|| Updated the engraftment statuses for questions 167 – 172. The engraftment status have been updated (struck out text has been deleted and red text has been added) as follows:
|4/19/19||Appendix J: Reporting Comorbidities||Add|| Added (in red below) instruction for reporting a cardiac comorbidity:
The presence of one or more of the following:
|4/19/19||Appendix D: How to Distinguish Infusion Types||Modify|| Updated the Co-infusion (with HCT) section to reflect updated cellular therapy forms (added text in red below)
When reporting co-infusions, the Cellular Therapy Product form (4003) and Cellular Therapy Infusion form (4006)
|4/19/19||Amyloidosis Response Criteria||Modify|| Modified the following sections (removed text is struck out below, added text is in red) of the Amyloidosis Response Criteria:
|4/19/19||2450: Post-TED||Modify||Provided additional instruction and examples for reporting the current disease status in Questions 237-238.|
|4/11/19||2450: Post-TED||Modify||Updated the instruction on how to report Dexamethasone if given for disease relapse or progression post-HCT. Dexamethasone should be reported as “Other Systemic Therapy,” not “Other Therapy.”|
|3/19/19||2450: Post-TED||Add|| Added the following red warning box instruction (in red below) below question 75 to clarify when to use the CCR option in the Disease Assessment at the Time of Best Response to HCT section of the Post-TED (2450) form:
Continued Complete Remission (CCR) should be reported for all patients who were already in CR at the start of the preparative regimen.